A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

NCT06816017 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Decision of the Sponsor.

Conditions

Non-muscle Invasive Bladder Cancer

Interventions

DRUG: Eciskafusp Alfa
DRUG: BCG Medac Strain

Sponsor

Hoffmann-La Roche